Corpus Intelligence IC Memo — ST. LUKES METHODIST HOSPITAL 2026-04-26 04:04 UTC
IC Memo — ST. LUKES METHODIST HOSPITAL
Investment Committee Memorandum | IA | 281 beds | Grade C | EBITDA uplift $27.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ST. LUKES METHODIST HOSPITAL

CCN 160045 | LINN, IA | 281 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ST. LUKES METHODIST HOSPITAL is a 281-bed safety-net/medicaid heavy in LINN, IA with $374.8M in net patient revenue and a 23.6% operating margin. The hospital serves a payer mix of 26.7% Medicare, 32.5% Medicaid, and 40.8% commercial.

Thesis: Platform Growth. Our ML models identify $27.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 23.6% to 31.0% (+736bps).

Net Revenue HCRIS$374.8M
Current EBITDA COMPUTED$88.6M
Operating Margin COMPUTED23.6%
Occupancy HCRIS58.5%
Revenue / Bed COMPUTED$1.3M
Net-to-Gross HCRIS29.9%
Distress Probability ML53.6%

2. Market Context & Competitive Position

124
IA Hospitals
-8.2%
State Median Margin
11
Comparable Hospitals

IA has 124 Medicare-certified hospitals with a median operating margin of -8.2%. The target's margin of 23.6% places it above the state median. Among 11 size-comparable peers (140-562 beds), the median margin is -12.8%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (140-562), prioritizing same-state peers. 11 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ST. LUKES METHODIST HOSPITAL (Target)IA281$374.8M23.6%
MERCY MEDICAL CENTER-DES MOINEIA556$635.8M-5.7%
MERCY MEDICAL CENTERIA216$401.1M-12.8%
GENESIS MEDICAL CENTER - DAVENIA322$391.9M-7.6%
MERCYONE NORTH IOWA MEDICAL CEIA199$390.3M-30.9%
SOUTHEAST IOWA REGIONAL MEDICAIA174$302.1M-24.2%
ALLEN MEMORIAL HOSPITALIA189$271.3M1.8%
MARY GREELEY MEDICAL CENTERIA150$220.4M-3.6%
ST. LUKES REGL MEDICAL CENTERIA173$181.1M0.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $27.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$7.9M+210bp18mo
Cost to Collect4.5%2.5%$7.5M+200bp12mo
Denial Rate Reduction12.0%6.5%$7.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$4.6M+122bp9mo
Clean Claim Rate88.0%96.0%$240K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$7.9M
Cost to Collect
$7.5M
Denial Rate Reduction
$7.4M
A/R Days Reduction
$4.6M
Clean Claim Rate
$240K
Total EBITDA Uplift$27.6M
Current EBITDA$88.6M
+ RCM Uplift+$27.6M
Pro Forma EBITDA$116.2M
Current Margin23.6%
Pro Forma Margin31.0%
WC Released (1x)$14.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$136.3M$860.3M6.31x44.5%
Base (11x exit)10.0x11.0x$136.3M$990.6M7.27x48.7%
Bull Case9.0x11.0x$122.7M$1.13B9.18x55.8%
Bull (12x exit)9.0x12.0x$122.7M$1.26B10.31x59.5%
Bear Case11.0x10.0x$149.9M$678.1M4.52x35.2%
Bear (11x exit)11.0x11.0x$149.9M$794.6M5.30x39.6%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (32.5%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims
HighElevated distress probabilityModel estimates 53.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 11 hospitals with 140-562 beds
  • Same-state prioritization (n=12)
  • Comp margins: P25=-25.0% / P50=-12.8% / P75=-4.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.